In other recent news, Hims & Hers Health, Inc. has announced a partnership with Novo Nordisk to offer Wegovy®, an FDA-approved obesity medication, through its platform. This collaboration aims to enhance obesity care by providing comprehensive health services alongside the medication, with a monthly subscription starting at $599. In financial developments, Citi analyst Daniel Grosslight has reduced Hims & Hers' stock price target to $25 from $27, maintaining a Sell rating. Grosslight anticipates that the company will exceed earnings estimates, although he expects a slowdown in core revenue growth. Meanwhile, the FDA has issued a warning letter concerning Hims & Hers' compounded topical finasteride products, citing safety concerns. BofA Securities maintained an Underperform rating for the company with a $22 price target, noting a slowdown in sales growth and concerns about the impact of the FDA's warning.